Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

NCT07556406 | Recruiting

• 1 other identifier: 25-43635
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. The study team is trying to determine whether these methods can provide more accurate measurements of GA progression toward the foveal center, the central part of the retina responsible for your sharpest, most detailed vision.

Conditions

Age-Related Macular Degeneration; Geographic Atrophy

Keywords

age-related macular degeneration; geographic atrophy

Outcome Measures

Primary Outcomes (1)

• Geographic atrophy progression rate

  Quantify the progression rate of geographic atrophy toward the foveal center over time

  1 year

Secondary Outcomes (1)

• Longitudinal progression of macular sensitivity over time

  1 year

Study Arms (4)

Non-central geographic atrophy not being treated

Patients with age-related macular degeneration who have geographic atrophy that does not involve the fovea.

Diagnostic Test: Optical coherence tomography; Diagnostic Test: Microperimetry

Intermediate age-related macular degeneration

Patients with intermediate age-related macular degeneration

Diagnostic Test: Optical coherence tomography; Diagnostic Test: Microperimetry

Non-central geographic atrophy currently being treated

Patients with non-central geographic atrophy from age-related macular degeneration who are currently receiving treatment for this condition.

Diagnostic Test: Optical coherence tomography; Diagnostic Test: Microperimetry

Non-central geographic atrophy initiating treatment

Patients with non-central geographic atrophy from age-related macular degeneration who will be starting to receive treatment for this condition.

Diagnostic Test: Optical coherence tomography; Diagnostic Test: Microperimetry

Interventions

Optical coherence tomography DIAGNOSTIC_TEST

High-resolution imaging method used to evaluate the structure of the retina

Also known as: OCT

Intermediate age-related macular degeneration; Non-central geographic atrophy currently being treated; Non-central geographic atrophy initiating treatment; Non-central geographic atrophy not being treated

Microperimetry DIAGNOSTIC_TEST

A functional test that maps retinal sensitivity by measuring how well you can detect lights in different areas of your vision.

Intermediate age-related macular degeneration; Non-central geographic atrophy currently being treated; Non-central geographic atrophy initiating treatment; Non-central geographic atrophy not being treated

Eligibility Criteria

• Age: 55 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with age-related macular degeneration.

You may qualify if:

• Subjects must be 55+ years of age Subjects in the "Intermediate AMD Observation Arm" must have intermediate age-related macular degeneration in one eye
• Subjects in the "GA Observation Arm", "GA Continuing Treatment Arm", and "GA Treatment Arm" must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.

You may not qualify if:

• Subjects with central involvement of GA. Central involvement is defined as geographic atrophy involving the foveal center point.
• Subjects with a baseline size of GA \> 17.5mm2 (7.0 Macular Photocoagulation Study Disc Areas).
• Subjects who are: pregnant women, adults who cannot consent for themselves, and those who use alcohol in excess. Excess alcohol use is defined by binge drinking (pattern of drinking that brings blood alcohol concentration levels to 0.08 g/dL) on 5 or more days in the past month.
• Evidence of retinal atrophy due to causes other than atrophic AMD. Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):
• Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy
• Branch or central retinal vein or artery occlusion
• Macular hole
• Pathologic myopia
• Uveitis
• Pseudovitelliform maculopathy
• Intraoperative surgery within the last 90 days prior to study eye enrollment

Sponsors & Collaborators

• University of California, San Francisco: lead

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

RECRUITING

MeSH Terms

Conditions

Macular Degeneration; Geographic Atrophy

Interventions

Tomography, Optical Coherence

Condition Hierarchy (Ancestors)

Retinal Degeneration; Retinal Diseases; Eye Diseases

Intervention Hierarchy (Ancestors)

Tomography, Optical; Optical Imaging; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis; Tomography; Investigative Techniques

Study Officials

• Jay Stewart, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jay M Stewart, MD

CONTACT

(628) 206-3123; eyestudy@ucsf.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 22, 2026
• First Posted: April 29, 2026
• Study Start: June 11, 2025
• Primary Completion (Estimated): June 11, 2027
• Study Completion (Estimated): June 11, 2027
• Last Updated: April 29, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)